We aim at understanding virus-host cell interactions to support broad antiviral therapies. We expand these insights into the wider field of cellular biology to reveal
processes important in other human diseases, such as cancer. In this way, we aim to discover new therapeutic strategies for various human health conditions.
For our research we apply CRISPR technology in all its flavors, from single gene editing to large scale functional genomic screens.
Discovery of the first drug-like
small molecule CRM1/XPO1 inhibitors
Licensed to Karyopharm Therapeutics and currently nearly worldwide used to treat patients with multiple myeloma or DLBCL
CRISPRres technique
(patent pending)
Development of a novel proprietary CRISPR-based target deconvolution method called CRISPRres to identify the target protein of small molecule inhibitors
Identification & characterization of TMEM106B
TMEM106B is a novel receptor for ACE2-independent SARS-CoV-2 infection
Identification of E3 ubiquitin ligase ASB8
The main recognition factor for selinexor-bound XPO1 protein degradation
The Rega Institute for Medical Research is an interdisciplinary research institute of the University of Leuven, that hosts a part of the Department of Microbiology and Immunology and the Medicinal Chemistry division of the Department of Pharmaceutical Sciences.
The institute is home to more than 300 scientists from different continents and backgrounds. It is located on the Gasthuisberg campus of the University Hospital of Leuven. Please consult the website if you want to learn more about the rich history of the Rega Institute and about the other research groups hosted by the institute.
